Pediatric Plasmablastic Lymphoma in the Setting of CD70 Deficiency.

Autor:	Baskin K; Department of Pediatric Allergy and Immunology., Vural O; Department of Pediatric Oncology., Haskologlu S; Can Sucak Research Laboratory for Translational Immunology., Erman B; Department of Medical Pathology, School of Medicine, Gazi University.; Institute of Child Health, Hacettepe University., Uyar Gocun P; Department of Pediatric Allergy and Immunology, School of Medicine, Ankara University, Ankara, Türkiye., Okur A; Department of Pediatric Oncology., Dogu F; Can Sucak Research Laboratory for Translational Immunology., Pinarli FG; Department of Pediatric Oncology., Ikinciogullari A; Can Sucak Research Laboratory for Translational Immunology.
Jazyk:	angličtina
Zdroj:	Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2024 Nov 01; Vol. 46 (8), pp. 438-441. Date of Electronic Publication: 2024 Sep 05.
DOI:	10.1097/MPH.0000000000002948
Abstrakt:	Combined immunodeficiency due to CD70 deficiency is characterized by increased susceptibility to infections, hypogammaglobulinemia, and malignancy. These patients typically present with chronic Epstein Barr virus (EBV) viremia, severe EBV-related hemophagocytic lymphohistiocytosis, lymphoproliferation, and Hodgkin and non-Hodgkin lymphomas. Plasmablastic lymphoma (PBL) is an extremely rare malignancy in all ages and is predominantly seen in male adults with human immunodeficiency virus infection. EBV infection, immunosuppression, solid organ transplantation, and age-related immune deterioration are also suspected causes of PBL. Nevertheless, there is scarce data about its association with primary immunodeficiencies in the literature. Here, we present the first case of a CD70 -deficient pediatric patient with PBL. Competing Interests: The authors declare no conflict of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu